AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 141 min read$BCAX

Mazumdar Claire sold $284K of BCAX

Mazumdar Claire (Chief Executive Officer) sold 10,000 shares of Bicara Therapeutics Inc. (BCAX) at an average of $28.42 ($28.42–$29.68, $0.28M total) across 2 trades on 2026-07-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mazumdar Claire
Published Jul 14, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCAX
Neutral
high confidence
Mentioned
$BCAX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCAXNeutralLow
01

Why it matters

Because the trades are open-market sales executed under a pre-arranged 10b5-1 plan, the disclosure is generally treated as low-signal for near-term fundamentals.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new company-specific catalyst in the filing.

03

What to watch

The sale size is modest relative to typical biotech insider holdings, and the transactions are explicitly pre-arranged, reducing signal strength.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed after-hours on July 14, covering sales executed July 10

Background

The article is an SEC Form 4 insider transaction disclosure for Bicara Therapeutics, reported by the CEO.

Company-level read

Ticker impact

$BCAXNeutralHigh confidence
Context

Bicara Therapeutics CEO Mazumdar Claire sold 10,000 shares in open-market transactions totaling about $284.2K, per Form 4 filed July 14.

Expected impact

Likely minimal near-term impact; any effect is more about optics than fundamentals.

Evidence & confidence

The filing specifies a pre-arranged 10b5-1 plan and provides only sale details, not guidance, trial results, or corporate actions.

Market effects

Sector

No sector read-through; this is an issuer-specific insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a lack of conviction.

Key entities

  • issuer
    Bicara Therapeutics Inc.

    Subject of the Form 4 insider sale disclosure.

  • insider
    Mazumdar Claire

    CEO and officer/director who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCAX insider trading history →

Related articles

AUG 18
$BCAXMed

Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics (BCAX) reported Q2 2026 earnings, highlighting $497.3M in cash and marketable securities, a net loss of $55.4M, and R&D expenses of $45.8M. The company is on track for FORTIFI-HN01 study enrollment by year-end 2026, with interim analysis expected in mid-2027. Management discussed leadership transitions and strategic focus on HPV-negative head and neck cancer, as well as exploratory colorectal cancer cohorts.

fool.com7 min
AUG 12
$BCAXMed

Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances

Bicara Therapeutics (NASDAQ:BCAX) shares rose about 3.3% pre-market after the company said enrollment is progressing in its pivotal FORTIFI-HN01 study and it remains on track for an interim analysis in mid-2027. Bicara reported Q2 2026 net loss of $55.4M, or $0.82 per share, with higher R&D and G&A. Cash and securities were $497.3M, expected to fund operations into 1H 2029.

yahoo.com4 min
AUG 11
$BCAXMed

Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

Bicara Therapeutics (Nasdaq: BCAX) reported Q2 2026 progress and announced leadership changes. Ryan Cohlhepp will become CEO effective Jan 2027, succeeding Claire Mazumdar, who will move to Vice Chair and Strategic Advisor. Tanya Green becomes COO, and Jenn Larson becomes CFO. The company said it is on track for year-end enrollment in the FORTIFI-HN01 pivotal trial, with interim topline results expected mid-2027.

finanznachrichten.de6 min
AUG 11
$BCAXMed

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire

SEC EDGAR 8-K6 min